Health & Fitness
Mon, April 11, 2011Sun, April 10, 2011Sat, April 9, 2011Fri, April 8, 2011Thu, April 7, 2011Wed, April 6, 2011Tue, April 5, 2011Mon, April 4, 2011Sun, April 3, 2011Sat, April 2, 2011Fri, April 1, 2011Thu, March 31, 2011Wed, March 30, 2011Tue, March 29, 2011Mon, March 28, 2011Sun, March 27, 2011Fri, March 25, 2011Thu, March 24, 2011Wed, March 23, 2011Tue, March 22, 2011Mon, March 21, 2011Sun, March 20, 2011Fri, March 18, 2011Thu, March 17, 2011Dyax Corp. to Present at the Needham & Company Healthcare Conference
Published in Health and Fitness on Wednesday, March 30th 2011 at 13:35 GMT by Market Wire
CAMBRIDGE, Mass.--([ BUSINESS WIRE ])--[ Dyax Corp. ] (NASDAQ: DYAX), a developer of novel biotherapeutics for unmet medical needs, announced today that Gustav A. Christensen, President and Chief Executive Officer of Dyax, will present at the Needham & Company 10th Annual Healthcare Conference, being held April 5-6, 2011 at the New York Palace Hotel in New York City. Mr. Christensen will provide a corporate update regarding the Companya™s three major business franchises a" [ KALBITOR® (ecallantide) ], the [ Licensing and Funded Research Program ] (LFRP) and [ Research and Development ] efforts. The Dyax presentation is scheduled for Wednesday, April 6 at 11:20 AM ET.
The Dyax presentation will be webcast live and may be accessed by visiting the Investor Relations section of the company website at [ www.dyax.com ]. The webcast will also be available on the Dyax website for a limited period of time following the conference.
About Dyax
Dyax is a fully integrated biopharmaceutical company focused on discovering, developing and commercializing novel biotherapeutics for unmet medical needs. The Companya™s lead product, ecallantide, has been approved under the brand name KALBITOR® in the United States for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older.
Dyax is commercializing KALBITOR in the United States independently, and establishing strategic partnerships to develop and commercialize ecallantide for the treatment of HAE in key regions worldwide. Currently, Dyax has partnership agreements for regions including Europe, Japan, Russia, the Middle East, Israel, North Africa, Australia and New Zealand. The company is also exploring other potential indications for ecallantide, either alone or through partnerships, including drug-induced angioedema and retinal vein occlusion-induced macular edema.
Ecallantide and other compounds in Dyaxa™s pipeline were identified using its patented phage display technology, which rapidly selects compounds that bind with high affinity and specificity to therapeutic targets. Dyax leverages this technology broadly as part of its Licensing and Funded Research Program (LFRP), which has 75 revenue generating licenses and collaborations for therapeutic discovery, as well as for affinity separations, diagnostic imaging, and research reagents. The success of the companya™s LFRP royalty portfolio is illustrated by the programa™s advanced licensee pipeline that includes 17 candidates in clinical development. Of them, four candidates are in Phase 3 clinical trials, four are in Phase 2 and nine are in Phase 1.
